-
Product Insights
New![]()
Net Present Value Model: Immatics NV’s IMA-201
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Immatics NV’s IMA-203
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203CD8 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMA-203CD8 in Solid Tumor Drug Details: IMA-203CD8 is under development for the treatment of multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-950 in Astrocytoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMA-950 in Astrocytoma Drug Details: IMA-950 is under development for the treatment of relapsing glioblastoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-950 in Oligodendroglioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMA-950 in Oligodendroglioma Drug Details: IMA-950 is under development for the treatment of relapsing glioblastoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMA-203 in Melanoma Drug Details: IMA-203 is under development for the treatment of solid tumors...
-
Company Insights
New![]()
Innovation and Patenting activity of IMA Industria Macchine Automatiche SpA Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of IMA Industria Macchine Automatiche SpA Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-201 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMA-201 in Solid Tumor Drug Details: IMA-201 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203CD8 in Uveal Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMA-203CD8 in Uveal Melanoma Drug Details:IMA-203CD8 is under development for the treatment of multiple solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203CD8 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMA-203CD8 in Solid Tumor Drug Details:IMA-203CD8 is under development for the treatment of multiple solid tumors...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.